Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
Colorcon
McKinsey
Express Scripts

Last Updated: August 11, 2022

Investigational Drug Information for RDEA3170


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for RDEA3170?

RDEA3170 is an investigational drug.

There have been 16 clinical trials for RDEA3170. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2013.

The most common disease conditions in clinical trials are Gout, Hyperuricemia, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Ardea Biosciences, Inc., AstraZeneca, and Clinical Laboratory: USA.

There are fourteen US patents protecting this investigational drug and one hundred and ninety-eight international patents.

Recent Clinical Trials for RDEA3170
TitleSponsorPhase
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and HyperuricaemiaAstraZenecaPhase 2
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UAAnalytical Laboratory (Pharmacokinetic Sample Analysis): USAPhase 2
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UAClinical Laboratory: USAPhase 2

See all RDEA3170 clinical trials

Clinical Trial Summary for RDEA3170

Top disease conditions for RDEA3170
Top clinical trial sponsors for RDEA3170

See all RDEA3170 clinical trials

US Patents for RDEA3170

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RDEA3170 See Plans and Pricing 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same ARDEA BIOSCIENCES, INC. (San Diego, CA) See Plans and Pricing
RDEA3170 See Plans and Pricing Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN) See Plans and Pricing
RDEA3170 See Plans and Pricing Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN) See Plans and Pricing
RDEA3170 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
RDEA3170 See Plans and Pricing URAT1 inhibitor Nippon Chemiphar Co., Ltd. (Tokyo, JP) J-Pharma Co., Ltd. (Kanagawa, JP) DeThree Res. Lab. Inc. (Ibaraki, JP) See Plans and Pricing
RDEA3170 See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RDEA3170

Drugname Country Document Number Estimated Expiration Related US Patent
RDEA3170 Australia AU2012332154 2031-11-03 See Plans and Pricing
RDEA3170 Brazil BR112014010495 2031-11-03 See Plans and Pricing
RDEA3170 Canada CA2852490 2031-11-03 See Plans and Pricing
RDEA3170 China CN104023723 2031-11-03 See Plans and Pricing
RDEA3170 China CN106963761 2031-11-03 See Plans and Pricing
RDEA3170 Denmark DK2776028 2031-11-03 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
Colorcon
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.